ClinicalTrials.gg
TerminatedNCT03207815HUMBOLDTUpdated Jan 21, 2022Results posted

Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis

A Phase 2 interventional study of Filgotinib and Placebo to match filgotinib in Noninfectious Uveitis, sponsored by Gilead Sciences. Terminated at 24 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-21.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Why this study was terminated
Development program terminated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 139 studies in Uveitis with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Uveitis · United States.

Enrollment
30th of 100
74 · median 19
Started
2017
with 6 others
Phase 2
28 of 139
none open now
Registered
107th of 139
by date

Among the 139 studies in Uveitis with a site in United States, this one is the 30th largest by enrollment of the 100 interventional ones that give a count, is one of 7 that started in 2017, is one of 28 in phase 2, and was the 107th registered.

Uveitis

300 studies on the registry are indexed under Uveitis; 32 are open to participants now.

Browse Uveitis studies →

Open to participants now

7 of the 139 studies in Uveitis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Uveitis studies recruiting now, 13 (59%) set no upper age limit and 9 (41%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Uveitis with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of filgotinib versus placebo for the treatment of the signs and symptoms of noninfectious uveitis as measured by the percentage of participants failing treatment for active noninfectious uveitis by Week 24.

03

Conditions studied

  • Noninfectious Uveitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Is diagnosed with active noninfectious intermediate-, posterior-, or pan-uveitis
  • Must have active uveitic disease at the Day 1/Baseline visit as defined by the presence of at least 1 of the following parameters in at least one eye despite 2 weeks of maintenance therapy with oral prednisone (≥ 10 mg/day to ≤ 60 mg/day) or an oral equivalent:

    • Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion
    • ≥ 2+ anterior chamber cells per the Standardization of Uveitis Nomenclature (SUN) criteria
    • ≥ 2+ vitreous haze per the National Eye Institute/Standardization of Uveitis Nomenclature (NEI/SUN) criteria
  • No evidence of active tuberculosis (TB) or untreated latent TB

Key Exclusion Criteria:

  • Participants with elevated intraocular pressures and/or severe glaucoma
  • Confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus (CMV), Human T-Lymphotropic Virus Type 1 (HTLV-1), Whipple's disease, Herpes Zoster virus (HZV), Lyme disease, toxoplasmosis and herpes simplex virus (HSV)

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Filgotinib

    Participants will receive filgotinib 200 milligrams (mg) once daily for up to 52 weeks along with a standardized prednisone burst of 60 milligrams per day (mg/day) at Day 1/Baseline followed by a protocol-defined mandatory taper schedule up to Week 15.

    Drug: Filgotinib · Drug: Prednisone

  • Placebo comparator
    Placebo

    Participants will receive placebo to match filgotinib once daily for up to 52 weeks along with a standardized prednisone burst of 60 mg/day at Day 1/Baseline followed by a protocol-defined mandatory taper schedule up to Week 15.

    Drug: Placebo to match filgotinib · Drug: Prednisone

Interventions

  • Tablet(s) administered orally

    Also known as: GS-6034, GLPG0634

  • DrugPlacebo to match filgotinib

    Tablet(s) administered orally

  • Tablet(s) administered orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Failing Treatment for Active NonInfectious Uveitis by Week 24

    Treatment failure was a participant meeting at least 1 of these criteria in at least 1 eye: New active, inflammatory lesions relative to Day 1/Baseline (all visits starting Week (Wk) 6); Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (change of Grade 0 to Grade 2+/Grade 0.5+ to Grade 3+) (all visits after Wk 6) relative to best state (RBS) achieved in Anterior Chamber (AC) cell grade (Standardization of Uveitis Nomenclature \[SUN\] criteria)\[AC cell grades range from 0 (0 cells) to 4+ (\>50 cells), higher scores=severe uveitis\]; Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (all visits after Wk 6) RBS achieved in Vitreous Haze (VH) grade (National Eye Institute \[NEI\]/SUN criteria)\[VH grades range from 0 (no evident VH) to 4+ (optic nerve head is obscured), higher scores=severe uveitis\]; Worsening of best corrected visual acuity (BCVA) by ≥15 letters RBS achieved (all visits starting Wk 6), measured by an eye chart, fewer correct letters=severe uveitis.

    Time frame: Week 6 through Week 24

Secondary outcomes

  1. Time to Treatment Failure on or After Week 6

    Treatment failure was a participant meeting at least 1 of these criteria in at least 1 eye: New active, inflammatory lesions relative to Day 1/Baseline (all visits starting Wk 6); Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (change of Grade 0 to Grade 2+/Grade 0.5+ to Grade 3+) (all visits after Wk 6) relative to best state (RBS) achieved in AC cell grade (SUN criteria) \[AC cell grades range from 0 (0 cells) to 4+ (\>50 cells), higher scores=severe uveitis\]; Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (all visits after Wk 6) RBS achieved in VH grade (NEI/SUN criteria) \[VH grades range from 0 (no evident VH) to 4+ (optic nerve head is obscured), higher scores=severe uveitis\]; Worsening of BCVA by ≥15 letters RBS achieved (all visits starting Wk 6), measured by an eye chart, fewer correct letters=severe uveitis.

    Time frame: Week 6 through Week 52

  2. Change in Vitreous Haze (VH) Grade in Each Eye (NEI/SUN Criteria), From Best State Achieved Prior to Week 6 to Week 52 or End of Treatment (EOT) Visit or Early Termination (ET)

    Grading of VH was based on the publication from the NEI which has also been adapted by the SUN working group. VH grades range from 0 (no evident VH) to 4+ (optic nerve head is obscured), with higher scores indicating greater severity of uveitis. A negative change from best state value obtained prior to Week 6 indicates improvement.

    Time frame: Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks)

  3. Change in Anterior Chamber (AC) Cell Grade in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET

    The number of AC cells observed within a 1 mm × 1 mm slit beam were recorded for each eye. The reported number was used to determine the grade according to the SUN criteria. AC cell grades range from 0 (0 cells in field) to 4+ (\>50 cells in field), with higher scores indicating more cells visible in the AC and greater severity of uveitis. A negative change from best state value obtained prior to Week 6 indicates improvement.

    Time frame: Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks)

  4. Change in Logarithm of the Minimal Angle of Resolution (logMAR) Best Corrected Visual Acuity (BCVA) in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET

    BCVA is the best possible vision that an eye can achieve with the set of glasses or contact lenses. A refraction test was performed to measure the appropriate lens strength to focus light on the retina. Using the appropriate corrective lenses based on that visit's refraction, participant's BCVA was measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. In the ETDRS system, 15 letters is equal to a change in 3 lines of visual acuity. If the participant is unable to read letters on a testing chart, visual acuity is described as ranging from ability to count fingers, recognize hand movements, or light perception. The smaller BVCA score indicates greater severity of uveitis. A positive change from best state value obtained prior to Week 6 indicates improvement.

    Time frame: Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks)

  5. Log Change in Central Retinal Thickness in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET

    Central retinal thickness is measured by optical coherence tomography (OCT). Central retinal thickness is defined as the thickness of the retina in the center of the foveal pit (1 mm subfield). The larger central retinal thickness value indicates greater severity of uveitis. A negative change from best state value obtained prior to Week 6 indicates improvement.

    Time frame: Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks)

  6. Time to Development of Macular Edema in At Least One Eye on or After Week 6

    Time in weeks until the development of Macular edema or Week 52 or EOT or ET. Macular edema is determined by OCT and is defined as central retinal thickness ≥ 300 microns if using Cirrus machine, or ≥ 315 microns if using Spectralis machine.

    Time frame: Week 6 through Week 52

  7. Plasma Concentration of Filgotinib

    Time frame: Day 1 post dose, Weeks 4 and 6 predose, Week 12 post dose, Weeks 24, 36, 52 (EOT), ET at any time

  8. Plasma Concentration of Metabolite, GS-829845

    Time frame: Day 1 post dose, Weeks 4 and 6 predose, Week 12 post dose, Weeks 24, 36, 52 (EOT), ET at any time

07

Results

Posted Jan 21, 2022
Limitations and caveats
Study was terminated early due to termination of the development program. Due to early termination and small sample size, pharmacokinetic (PK) analysis was not performed for this study.

Participant flow

Participants were enrolled at study sites in the United States, the United Kingdom, Canada, Australia, Germany, Israel, and New Zealand. The first participant was screened on 26 July 2017. The last study visit occurred on 22 April 2021.

Participant flow — Overall Study
MilestoneFilgotinibPlacebo
Started3836
Completed3029
Not completed87
Withdrew: Protocol violation31
Withdrew: Adverse event12
Withdrew: Lost to follow-up12
Withdrew: Investigator's discretion11
Withdrew: Lack of efficacy01
Withdrew: Pregnancy/partner pregnancy10
Withdrew: Withdrew consent10

Outcome measures

PrimaryPercentage of Participants Failing Treatment for Active NonInfectious Uveitis by Week 24

Treatment failure was a participant meeting at least 1 of these criteria in at least 1 eye: New active, inflammatory lesions relative to Day 1/Baseline (all visits starting Week (Wk) 6); Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (change of Grade 0 to Grade 2+/Grade 0.5+ to Grade 3+) (all visits after Wk 6) relative to best state (RBS) achieved in Anterior Chamber (AC) cell grade (Standardization of Uveitis Nomenclature \[SUN\] criteria)\[AC cell grades range from 0 (0 cells) to 4+ (\>50 cells), higher scores=severe uveitis\]; Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (all visits after Wk 6) RBS achieved in Vitreous Haze (VH) grade (National Eye Institute \[NEI\]/SUN criteria)\[VH grades range from 0 (no evident VH) to 4+ (optic nerve head is obscured), higher scores=severe uveitis\]; Worsening of best corrected visual acuity (BCVA) by ≥15 letters RBS achieved (all visits starting Wk 6), measured by an eye chart, fewer correct letters=severe uveitis.

Time frame:
Week 6 through Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Failing Treatment for Active NonInfectious Uveitis by Week 24
percentage of participantsFilgotinibPlacebo
Percentage of Participants Failing Treatment for Active NonInfectious Uveitis by Week 2437.5 (19.2 to 55.8)67.6 (50.5 to 84.8)
Statistical analysis
  • Filgotinib vs Placebo · Cochran-Mantel-Haenszel · p = 0.0064 (P-value was estimated from the Cochran-Mantel-Haenszel (CMH) test, adjusted for the stratification factors.) · Difference in treatment failure rate: -30.1 · 95% CI -56.2 to -4.1Participants with missing values on treatment failure status were analyzed as treatment failures using a nonresponder imputation (NRI) method.
SecondaryTime to Treatment Failure on or After Week 6

Treatment failure was a participant meeting at least 1 of these criteria in at least 1 eye: New active, inflammatory lesions relative to Day 1/Baseline (all visits starting Wk 6); Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (change of Grade 0 to Grade 2+/Grade 0.5+ to Grade 3+) (all visits after Wk 6) relative to best state (RBS) achieved in AC cell grade (SUN criteria) \[AC cell grades range from 0 (0 cells) to 4+ (\>50 cells), higher scores=severe uveitis\]; Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (all visits after Wk 6) RBS achieved in VH grade (NEI/SUN criteria) \[VH grades range from 0 (no evident VH) to 4+ (optic nerve head is obscured), higher scores=severe uveitis\]; Worsening of BCVA by ≥15 letters RBS achieved (all visits starting Wk 6), measured by an eye chart, fewer correct letters=severe uveitis.

Time frame:
Week 6 through Week 52
Reported as:
Median · weeks
Time to Treatment Failure on or After Week 6
weeksFilgotinibPlacebo
Time to Treatment Failure on or After Week 6NA (24.1 to NA)22.0 (12.1 to 47.0)
Statistical analysis
  • Filgotinib vs Placebo · Stratified Log-Rank Test · p = 0.0014 (P-value was derived from the log rank test stratified by the stratification factors.) · Stratified hazard ratio: 0.309 · 95% CI 0.144 to 0.663Stratified hazard ratio (95% confidence interval \[CI\]) were derived from the Cox model stratified by the stratification factors.
SecondaryChange in Vitreous Haze (VH) Grade in Each Eye (NEI/SUN Criteria), From Best State Achieved Prior to Week 6 to Week 52 or End of Treatment (EOT) Visit or Early Termination (ET)

Grading of VH was based on the publication from the NEI which has also been adapted by the SUN working group. VH grades range from 0 (no evident VH) to 4+ (optic nerve head is obscured), with higher scores indicating greater severity of uveitis. A negative change from best state value obtained prior to Week 6 indicates improvement.

Time frame:
Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks)
Reported as:
Mean · score
Change in Vitreous Haze (VH) Grade in Each Eye (NEI/SUN Criteria), From Best State Achieved Prior to Week 6 to Week 52 or End of Treatment (EOT) Visit or Early Termination (ET)
scoreFilgotinibPlacebo
Left Eye: Best State Prior to Week 60.3 ± 0.400.2 ± 0.33
Right Eye: Best State Prior to Week 60.3 ± 0.360.3 ± 0.45
Left Eye: Change From Best State at Week 52/EOT/ET0.1 ± 0.790.3 ± 0.75
Right Eye: Change From Best State at Week 52/EOT/ET0.1 ± 0.620.2 ± 0.66
Statistical analysis
  • Filgotinib vs Placebo · Repeated Measure ANCOVA · p = 0.3550 (P-value was estimated using a repeated measure Analysis of Covariance (ANCOVA) model which included treatment, eye, interaction of treatment and eye, stratification factors and best state value.) · Least squares mean treatment difference: -0.1 · 95% CI -0.4 to 0.2Treatment difference in Least Squares (LS)-means (95% CI) were obtained from the repeated measure ANCOVA model.
SecondaryChange in Anterior Chamber (AC) Cell Grade in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET

The number of AC cells observed within a 1 mm × 1 mm slit beam were recorded for each eye. The reported number was used to determine the grade according to the SUN criteria. AC cell grades range from 0 (0 cells in field) to 4+ (\>50 cells in field), with higher scores indicating more cells visible in the AC and greater severity of uveitis. A negative change from best state value obtained prior to Week 6 indicates improvement.

Time frame:
Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks)
Reported as:
Mean · score
Change in Anterior Chamber (AC) Cell Grade in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET
scoreFilgotinibPlacebo
Left Eye: Best State Prior to Week 60.0 ± 0.090.1 ± 0.19
Right Eye: Best State Prior to Week 60.0 ± 0.120.1 ± 0.25
Left Eye: Change From Best State at Week 52/EOT/ET0.2 ± 0.590.6 ± 0.87
Right Eye: Change From Best State at Week 52/EOT/ET0.2 ± 0.530.7 ± 1.05
Statistical analysis
  • Filgotinib vs Placebo · Repeated Measure ANCOVA · p = 0.0145 (P-value was estimated using a repeated measure ANCOVA model which included treatment, eye, interaction of treatment and eye, stratification factors and best state value.) · Ls mean treatment difference: -0.4 · 95% CI -0.8 to -0.1Treatment difference in LS-means (95% CI) were obtained from the repeated measure ANCOVA model.
SecondaryChange in Logarithm of the Minimal Angle of Resolution (logMAR) Best Corrected Visual Acuity (BCVA) in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET

BCVA is the best possible vision that an eye can achieve with the set of glasses or contact lenses. A refraction test was performed to measure the appropriate lens strength to focus light on the retina. Using the appropriate corrective lenses based on that visit's refraction, participant's BCVA was measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. In the ETDRS system, 15 letters is equal to a change in 3 lines of visual acuity. If the participant is unable to read letters on a testing chart, visual acuity is described as ranging from ability to count fingers, recognize hand movements, or light perception. The smaller BVCA score indicates greater severity of uveitis. A positive change from best state value obtained prior to Week 6 indicates improvement.

Time frame:
Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks)
Reported as:
Mean · logMAR
Change in Logarithm of the Minimal Angle of Resolution (logMAR) Best Corrected Visual Acuity (BCVA) in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET
logMARFilgotinibPlacebo
Left Eye: Best State Prior to Week 60.09 ± 0.1950.07 ± 0.209
Right Eye: Best State Prior to Week 60.09 ± 0.1930.12 ± 0.280
Left Eye: Change From Best State at Week 52/EOT/ET0.03 ± 0.1540.05 ± 0.112
Right Eye: Change From Best State at Week 52/EOT/ET-0.01 ± 0.1160.07 ± 0.144
Statistical analysis
  • Filgotinib vs Placebo · Repeated Measure ANCOVA · p = 0.0389 (P-value was estimated using a repeated measure ANCOVA model which included treatment, eye, interaction of treatment and eye, stratification factors and best state value.) · Ls mean treatment difference: -0.05 · 95% CI -0.10 to -0.00Treatment difference in LS-means (95% CI) were obtained from the repeated measure ANCOVA model.
SecondaryLog Change in Central Retinal Thickness in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET

Central retinal thickness is measured by optical coherence tomography (OCT). Central retinal thickness is defined as the thickness of the retina in the center of the foveal pit (1 mm subfield). The larger central retinal thickness value indicates greater severity of uveitis. A negative change from best state value obtained prior to Week 6 indicates improvement.

Time frame:
Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks)
Reported as:
Mean · log microns
Log Change in Central Retinal Thickness in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET
log micronsFilgotinibPlacebo
Left Eye: Best State Prior to Week 62.45 ± 0.0592.46 ± 0.097
Right Eye: Best State Prior to Week 62.47 ± 0.0562.44 ± 0.104
Left Eye: Change From Best State at Week 52/EOT/ET0.01 ± 0.0620.04 ± 0.080
Right Eye: Change From Best State at Week 52/EOT/ET0.01 ± 0.0490.03 ± 0.055
Statistical analysis
  • Filgotinib vs Placebo · Repeated Measure ANCOVA · p = 0.0340 (P-value was estimated using a repeated measure ANCOVA model which included treatment, eye, interaction of treatment and eye, OCT machine, and best state value.) · Ls mean treatment difference: -0.02 · 95% CI -0.05 to -0.00Treatment difference in LS-means (95% CI) were obtained from the repeated measure ANCOVA model.
SecondaryTime to Development of Macular Edema in At Least One Eye on or After Week 6

Time in weeks until the development of Macular edema or Week 52 or EOT or ET. Macular edema is determined by OCT and is defined as central retinal thickness ≥ 300 microns if using Cirrus machine, or ≥ 315 microns if using Spectralis machine.

Time frame:
Week 6 through Week 52
Reported as:
Median · weeks
Time to Development of Macular Edema in At Least One Eye on or After Week 6
weeksFilgotinibPlacebo
Time to Development of Macular Edema in At Least One Eye on or After Week 67.8 (6.1 to NA)12.3 (6.1 to NA)
Statistical analysis
  • Filgotinib vs Placebo · Stratified Log-Rank Test · p = 0.5893 (P-value was derived from the log rank test stratified by the stratification factors.) · Stratified hazard ratio: 1.193 · 95% CI 0.625 to 2.277Stratified hazard ratio (95% CI) were derived from the Cox model stratified by the stratification factors.
SecondaryPlasma Concentration of Filgotinib
Time frame:
Day 1 post dose, Weeks 4 and 6 predose, Week 12 post dose, Weeks 24, 36, 52 (EOT), ET at any time
Reported as:
Mean · nanograms per millilitre (ng/ml)
Plasma Concentration of Filgotinib
nanograms per millilitre (ng/ml)Filgotinib
Day 1 Postdose748.5 ± 1043.84
Week 4 Predose173.3 ± 364.46
Week 6 Predose133.9 ± 306.18
Week 12 Postdose1088.7 ± 856.57
Week 24 Single Anytime397.5 ± 561.57
Week 36 Single Anytime295.7 ± 420.25
Week 52 Single Anytime195.2 ± 344.54
Early Termination Single Anytime434.8 ± 478.72
SecondaryPlasma Concentration of Metabolite, GS-829845
Time frame:
Day 1 post dose, Weeks 4 and 6 predose, Week 12 post dose, Weeks 24, 36, 52 (EOT), ET at any time
Reported as:
Mean · ng/ml
Plasma Concentration of Metabolite, GS-829845
ng/mlFilgotinib
Day 1 Postdose230.8 ± 317.98
Week 4 Predose2085.6 ± 924.91
Week 6 Predose2107.7 ± 749.28
Week 12 Postdose3237.0 ± 1180.74
Week 24 Single Anytime3478.1 ± 1137.63
Week 36 Single Anytime2944.3 ± 1130.84
Week 52 Single Anytime2510.7 ± 1732.59
Early Termination Single Anytime2171.0 ± 1224.77

Adverse events

Collected over Adverse Events: First dose date up to 30 days after the last dose of study drug (maximum exposure up to 57 weeks); All-Cause Mortality: From randomization up to 57 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Filgotinib0/38 (0%)5/37 (13.5%)28/37 (75.7%)
Placebo0/36 (0%)2/35 (5.7%)19/35 (54.3%)
Most frequent serious events
Most frequent serious events
EventFilgotinibPlacebo
Retinal vasculitisEye disorders0/371/35
Urinary tract infectionInfections and infestations0/371/35
UveitisEye disorders1/370/35
Inflammatory bowel diseaseGastrointestinal disorders1/370/35
Covid-19Infections and infestations1/370/35
Spinal stenosisMusculoskeletal and connective tissue disorders1/370/35
EpilepsyNervous system disorders1/370/35
Suicidal ideationPsychiatric disorders1/370/35
Bladder prolapseRenal and urinary disorders1/370/35
Most frequent other events
Showing 10 of 44
Most frequent other events
EventFilgotinibPlacebo
HeadacheNervous system disorders3/377/35
Visual impairmentEye disorders5/371/35
Dry eyeEye disorders2/374/35
InsomniaPsychiatric disorders4/374/35
Abdominal painGastrointestinal disorders4/370/35
NauseaGastrointestinal disorders4/371/35
Urinary tract infectionInfections and infestations4/373/35
FatigueGeneral disorders3/373/35
HypertensionVascular disorders1/373/35
PhotopsiaEye disorders3/370/35

Baseline characteristics

Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)FilgotinibPlaceboTotal
Mean48 ± 15.143 ± 15.746 ± 15.5
Sex: Female, Male
Sex: Female, Male(Participants)FilgotinibPlaceboTotal
Female232043
Male141529
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FilgotinibPlaceboTotal
Ethnicity — Hispanic or Latino41014
Ethnicity — Not Hispanic or Latino322557
Ethnicity — Not Permitted101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FilgotinibPlaceboTotal
Race — Asian404
Race — Black or African American2810
Race — Native Hawaiian or Pacific Islander101
Race — White292655
Race — Other112
Region of Enrollment
Region of Enrollment(participants)FilgotinibPlaceboTotal
United States293160
United Kingdom426
Canada202
Australia101
Germany011
Israel011
New Zealand101
08

Study locations

24 sites
  • Stanford Byers Eye Institute
    Palo Alto, California 94303, United States
  • Colorado Retina Associates PC
    Golden, Colorado 80401, United States
  • Northwestern Medical Group
    Chicago, Illinois 60611, United States
  • Illinois Retina Associates
    Oak Park, Illinois 60304, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • Associated Retinal Consultants PC
    Royal Oak, Michigan 48073, United States
  • Metropolitan Eye Research and Surgery Institute
    Palisades Park, New Jersey 07650, United States
  • Duke University Eye Center
    Durham, North Carolina 27710, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Cleveland Clinic Foundation-Cole Eye Institute
    Cleveland, Ohio 44191, United States
  • Oregon Health Science University-Casey Eye Institute
    Portland, Oregon 97239, United States
  • Mid Atlantic Retina
    Philadelphia, Pennsylvania 19107, United States
  • Texas Retina Associates - Fort Worth
    Fort Worth, Texas 76104, United States
  • Foresight Studies, LLC
    San Antonio, Texas 78240, United States
  • university of Wisconsin-Madison
    Madison, Wisconsin 53705, United States
  • Lions Eye Institute
    Nedlands, Western Australia 6009, Australia
  • Retina Consultants
    Vancouver, V5Z 0E9, Canada
  • St. Franziskus Hospital
    Münster, Germany
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • Auckland Eye
    Remuera, 1050, New Zealand
  • Royal Liverpool University Hospital
    Liverpool, L7 8XP, United Kingdom
  • Moorfields Eye Hospital NHS Foundation Trust
    London, United Kingdom
  • Central Mancester Hospitals NHS Foundation Trust, Manchester Royal Eye Hospital
    Manchester, M13 9WL, United Kingdom
  • Eye Research Group Oxford, Oxford Eye Hospital
    Oxford, OX3 9DU, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Dec 2020, 41 months.

Results were first posted in Jan 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2017
First posted
Jul 5, 2017
StartActual
Jul 26, 2017
Primary completionActual
Dec 29, 2020
CompletionActual
Apr 22, 2021
Results first posted
Jan 21, 2022
Last update
Jan 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03207815
Lead sponsor
Gilead Sciences
Collaborators
Galapagos NV
Responsible party
Sponsor
First posted
Jul 5, 2017
Start date
Jul 26, 2017
Primary completion
Dec 29, 2020
Completion
Apr 22, 2021
Results posted
Jan 21, 2022
Last update
Jan 21, 2022

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion